Lexeo Therapeutics, Inc. Common StockLXEONASDAQ
Loading
Operating Expenses Over TimeStrong
Percentile Rank100
3Y CAGR+22.5%
5Y CAGR+85.6%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+22.5%/yr
Annual compound
5Y CAGR
+85.6%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
22x
Strong expansion
Streak
5 yr
Consecutive growthStrong
| Period | Value | YoY Change |
|---|---|---|
| TTM | $112.48M | +6.4% |
| 2024 | $105.77M | +54.4% |
| 2023 | $68.51M | +12.0% |
| 2022 | $61.16M | +17.0% |
| 2021 | $52.29M | +924.1% |
| 2020 | $5.11M | - |